Instructions Streptocide tablets 300 mg No. 100
Composition
active ingredient: sulfanilamide;
1 tablet contains streptocide (sulfanilamide) 300 mg;
excipients: potato starch, talc.
Dosage form
Pills.
Main physicochemical properties: solid, regular, round cylinders, the upper and lower surfaces of which are flat, the edges of the surfaces are beveled, with a dividing line, white or almost white in color.
Pharmacotherapeutic group
Antibacterial agents for systemic use. Short-acting sulfonamides.
ATX code J01E B06.
Pharmacological properties
Pharmacodynamics.
Streptocide disrupts the creation of so-called “germination factors” in microorganisms – folic, dehydrofolic acids, other compounds that have para-aminobenzoic acid (PABA) in their molecule. Due to the similarity of the structures of PABA and Streptocide, sulfonamide, as a competitive antagonist of the acid, is included in the metabolic chain of microorganisms and disrupts the metabolic processes in it, which leads to a bacteriostatic effect. Streptocide is a short-acting sulfonamide, which exhibits a bacteriostatic effect on streptococci, meningococci, pneumococci, gonococci, Escherichia coli, pathogens of toxoplasmosis and malaria. It does not affect anaerobic microorganisms.
Pharmacokinetics.
When administered orally, it is rapidly absorbed – the maximum concentration of streptocide in the blood is determined after 1-2 hours (within 4 hours it is detected in the cerebrospinal fluid); a 50% decrease in the maximum concentration in the blood occurs in less than 8 hours. Approximately 95% of the drug is excreted by the kidneys.
Indication
Infectious-inflammatory diseases caused by microorganisms sensitive to the drug: infectious diseases of the skin and mucous membranes (wounds, ulcers, bedsores), enterocolitis, pyelitis, cystitis.
Contraindication
Individual sensitivity to sulfonamides, sulfones or other components of the drug; history of severe toxic-allergic reactions to sulfonamides; suppression of bone marrow hematopoiesis; uncompensated heart failure; diseases of the hematopoietic system; anemia; leukopenia; Graves' disease; kidney and liver diseases (nephrosis, nephritis, liver failure, severe renal failure, acute hepatitis); hyperthyroidism; congenital deficiency of glucose-6-phosphate dehydrogenase; azotemia; porphyria.
Interaction with other medicinal products and other types of interactions
When used simultaneously:
with nonsteroidal anti-inflammatory drugs, sulfonylurea derivatives, antithrombotic agents, vitamin K antagonists - the effect of these drugs is enhanced;
with folic acid, bactericidal antibiotics (including penicillins, cephalosporins) - the effectiveness of sulfonamides decreases;
with bactericidal antibiotics, oral contraceptives - the effect of these drugs is reduced;
with para-aminosalicylic acid (PASA) and barbiturates – the activity of sulfonamides increases;
with erythromycin, lincomycin, tetracycline – antibacterial activity is mutually enhanced, the spectrum of action is expanded;
with rifampicin, streptomycin, monomycin, kanamycin, gentamicin, oxyquinoline derivatives (nitroxoline) - the antibacterial effect of the drugs does not change;
with nalidixic acid (Nevigramon) – sometimes antagonism is observed;
with chloramphenicol, nitrofurans - the total effect is reduced;
with drugs containing PABA esters (novocaine, anestezin, dicaine), the antibacterial activity of sulfonamides is inactivated.
Sulfonamides are not prescribed simultaneously with hexamethylenetetramine (urotropine), with antidiabetic drugs (sulfonylurea derivatives), with definin, neodicoumarin and other indirect anticoagulants.
Streptocide may enhance the effect and/or toxicity of methotrexate by displacing it from protein binding and/or weakening its metabolism.
When used simultaneously with other drugs that cause bone marrow suppression, hemolysis, or hepatotoxicity, toxic effects may develop.
Concomitant use with methenamine (urotropine) is not recommended due to an increased risk of crystalluria with acidic urine.
Phenylbutazone (butadione), salicylates and indomethacin can displace sulfonamides from their binding to plasma proteins, thereby increasing their concentration in the blood. When used together with para-aminosalicylic acid and barbiturates, the activity of sulfonamides increases; with chloramphenicol - the risk of agranulocytosis increases; with drugs containing para-aminobenzoic acid esters (novocaine, anestezin, dicaine), the antibacterial activity of sulfonamide is inactivated.
Application features
During treatment with the drug, it is necessary to systematically monitor kidney function, peripheral blood parameters, and blood glucose levels.
Sulfonamides should not be used to treat infections caused by group A beta-hemolytic streptococcus, as they do not eradicate it and, as a result, cannot prevent complications such as rheumatic fever and glomerulonephritis.
The drug should be prescribed with caution to patients with chronic heart failure, liver disease and impaired renal function. Streptocide should be prescribed with caution to patients with severe allergic diseases or bronchial asthma, with diseases of the blood system. If signs of a hypersensitivity reaction appear, the drug should be discontinued. In renal failure, cumulation of sulfonamide and its metabolites in the body is possible, which can lead to the development of a toxic effect.
Sulfonamides, including streptocide, should be used with caution in patients with diabetes mellitus, as sulfonamides can affect blood sugar levels. High doses of sulfonamides have a hypoglycemic effect.
Since sulfonamides are bacteriostatic, not bactericidal drugs, a full course of therapy is necessary to prevent recurrence of infection and the development of resistant forms of microorganisms.
Given the similarity of chemical structure, sulfonamides should not be used in people with hypersensitivity to furosemide, thiazide diuretics, carbonic anhydrase inhibitors, and sulfonylurea derivatives.
Patients need to consume sufficient fluids to prevent crystalluria and the development of urolithiasis.
Elderly people are at increased risk of developing severe adverse skin reactions, hematopoiesis suppression, thrombocytopenic purpura (the latter especially when combined with thiazide diuretics). The drug should be avoided in patients over 65 years of age due to the increased risk of severe adverse reactions.
It is recommended to avoid exposure to direct sunlight and artificial ultraviolet radiation, given the possibility of photosensitization when using sulfonamides.
During treatment, it is necessary to adhere to the dosage regimen, apply the recommended dose at intervals of 24 hours, do not miss a dose of the drug. In case of missing a dose, do not double the next dose.
If the signs of the disease do not disappear or, conversely, the state of health worsens, or undesirable effects occur, it is necessary to stop using the drug and consult a doctor regarding further use of the drug.
Use during pregnancy or breastfeeding
The drug is contraindicated during pregnancy or breastfeeding.
If treatment with the drug is necessary, breastfeeding should be discontinued.
Ability to influence reaction speed when driving vehicles or other mechanisms
Until the individual reaction to the drug is determined, one should refrain from driving or working with other mechanisms, since during treatment with sulfonamides, such adverse reactions from the nervous system as dizziness, convulsions, ataxia, drowsiness, depression, and psychosis are possible.
Method of administration and doses
Take orally during or after meals, drinking 150-200 ml of water. A single dose for adults and children over 12 years of age is 600 mg-1.2 g, daily dose - 3-6 g. Divide the daily dose into 5 doses. Maximum doses for adults: single - 2 g, daily - 7 g.
A single dose for children aged 3 to 6 years is 300 mg, from 6 to 12 years is 300-600 mg. The frequency of administration for children is 4-6 times a day.
The maximum daily dose for children is 0.9-2.4 g.
The duration of treatment is determined by the doctor individually, depending on the severity and course of the disease, the localization of the process, and the effectiveness of therapy.
Children.
Used for children aged 3 years and over.
Overdose
Possible increased side effects.
Overdose may cause anorexia (lack of appetite), nausea, vomiting, colic-like pain, headache, drowsiness, dizziness, fainting. With prolonged use, fever, hematuria, crystalluria, cyanosis, tachycardia, paresthesia, diarrhea, cholestasis, renal failure with anuria, toxic hepatitis, leukopenia, agranulocytosis.
Treatment. In case of overdose, it is recommended to consult a doctor. Symptomatic therapy. Before providing medical care, wash the stomach with a 2% solution of sodium bicarbonate and take a suspension of activated charcoal or other enterosorbents. Drinking plenty of fluids, forced diuresis, hemodialysis are indicated.
Side effects
From the blood system: leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, hypoprothrombinemia, eosinophilia, hemolytic anemia with glucose-6-phosphate dehydrogenase deficiency.
Cardiovascular system: tachycardia, myocarditis.
Nervous system: headache; neurological reactions including aseptic meningitis; ataxia; mild intracranial hypotension; convulsions; dizziness; drowsiness/insomnia; fatigue; depression; peripheral or optic neuropathies; visual disturbances; psychosis; depressed state; paresthesia.
On the part of the digestive tract: thirst, dry mouth, dyspeptic phenomena, nausea, vomiting, diarrhea, anorexia, pancreatitis, pseudomembranous colitis.
On the part of the hepatobiliary system: increased activity of liver enzymes (alanine transaminase, aspartate transaminase, alkaline phosphatase), cholestatic hepatitis, hepatonecrosis, hepatomegaly, jaundice, cholestasis.
On the part of the urinary system: change in urine color (rich yellow-brown color), crystalluria with an acidic urine reaction; nephrotoxic reactions are possible: interstitial nephritis, tubular necrosis, renal failure, hematuria, shock kidney with anuria.
Skin and subcutaneous tissue disorders: skin hyperemia, skin rashes (including erythematous-squamous, papular), itching, urticaria, allergic dermatitis, photosensitivity, exfoliative dermatitis, erythema nodosum, cyanosis.
Allergic reactions: toxic epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome, systemic lupus erythematosus, serum sickness, anaphylactic reactions, angioedema, rhinitis.
General disorders: drug-induced fever, pain in the right hypochondrium and lower back.
Others: difficulty breathing, periarteritis nodosa, hypothyroidism, hypoglycemia. In rare cases, hypothyroidism may develop.
Expiration date
5 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
10 tablets in blisters.
10 tablets in a blister; 1 or 10 blisters in a cardboard pack.
Vacation category
According to the recipe.
Producer
JSC "Lubnypharm".
Address
Ukraine, 37500, Poltava region, Lubny, Barvinkova st., 16.
